cialis naturista

COVID-19: a respiratory vaccine effective in mice

Less known to the general public, mucosal vaccination via the mucus membranes could provide robust protection against SARS-CoV-2 infections. Immune cells in the nose and lungs are considered better prepared to encounter and block the virus that causes COVID-19.

An international research team has just demonstrated that its mucosal DNA vaccine is capable of ensuring the total survival of a group of mice infected with a version of the virus adapted to this species, whereas the latter kills 100% of unvaccinated mice.

Created using a vector developed by a CNRS researcher at the Immunology and New Concepts in ImmunoTherapy Laboratory (CNRS/INSERM/Nantes Université/Université Angers), differin modo de uso this vaccine acts in a manner similar to that of RNA vaccines on the market: DNA delivered by the vector enters the target cells, causing them to produce a SARS-CoV-2 protein and allowing the immune system to prepare itself by producing antibodies and lymphocytes against the virus.

The vaccine’s effectiveness against transmission between mice was not measured in this study, which is published online in Biomaterials. However, scientists hope that a vaccination method based on this principle could complement the current strategy, perhaps by providing better protection against transmission.

More information:
Si Sun et al, Respiratory mucosal vaccination of peptide-poloxamine-DNA nanoparticles provides complete protection against lethal SARS-CoV-2 challenge, Biomaterials (2022). DOI: 10.1016/j.biomaterials.2022.121907

Journal information:
Biomaterials

Source: Read Full Article